Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone [Seeking Alpha]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Seeking Alpha
Linda Marbán, Co-Founder, President, CEO & Director, stated the company's focus is on advancing Deramiocel for potential approval in Duchenne muscular dystrophy (DMD) and highlighted that "the U.S. Food and Drug Administration has stated that our response to our complete Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up Quick Insights The FDA has accepted the BLA for Deramiocel and set a PDUFA action date; label negotiations and potential advisory committee remain pending. Capricor has $318.1 million in cash and expects to fund operations into the fourth quarter of 2027, not counting potential product revenue or voucher monetization. The company is expanding manufacturing capacity for anticipated demand (targeting 2,500 patients/year) and building commercial infrastructure, including market access and physician education. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Exosome Research Market Analysis, Opportunity Forecasts Report 2026-2035 [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial ... [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics, Inc. GAAP EPS of -$0.62 misses by $0.08, revenue of $0M [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
CAPR
Earnings
- 3/12/26 - Miss
CAPR
Sec Filings
- 3/12/26 - Form 8-K
- 3/10/26 - Form 8-K
- 2/26/26 - Form SCHEDULE
- CAPR's page on the SEC website